收费全文 | 367篇 |
免费 | 14篇 |
国内免费 | 5篇 |
财政金融 | 14篇 |
工业经济 | 34篇 |
计划管理 | 126篇 |
经济学 | 43篇 |
综合类 | 45篇 |
运输经济 | 5篇 |
旅游经济 | 5篇 |
贸易经济 | 59篇 |
农业经济 | 18篇 |
经济概况 | 37篇 |
2024年 | 1篇 |
2023年 | 9篇 |
2022年 | 3篇 |
2021年 | 8篇 |
2020年 | 9篇 |
2019年 | 6篇 |
2018年 | 5篇 |
2017年 | 14篇 |
2016年 | 7篇 |
2015年 | 13篇 |
2014年 | 23篇 |
2013年 | 20篇 |
2012年 | 34篇 |
2011年 | 29篇 |
2010年 | 28篇 |
2009年 | 26篇 |
2008年 | 32篇 |
2007年 | 26篇 |
2006年 | 26篇 |
2005年 | 11篇 |
2004年 | 13篇 |
2003年 | 1篇 |
2002年 | 8篇 |
2001年 | 8篇 |
2000年 | 5篇 |
1999年 | 3篇 |
1998年 | 1篇 |
1997年 | 4篇 |
1996年 | 3篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
Materials and methods: HRs were sourced from a published systematic literature review and a meta-analysis of real-world evidence on the use of NOACs vs VKAs. Rivaroxaban, dabigatran, and apixaban vs VKAs were investigated. The efficacy outcomes included: a composite of ischaemic stroke and systemic embolism (IS/SE), ischaemic stroke (IS), and all-cause mortality. The safety analysis assessed major bleeding and intracranial haemorrhage (ICH).
Results: Superiority of NOACs vs VKAs was observed in 10/15 comparisons. Treating patients with rivaroxaban and dabigatran was associated with a reduced risk of IS and all-cause mortality compared to VKAs, with one death prevented every 22 and 32 patients, respectively, and one IS prevented every 206 and 166 patients, respectively. Rivaroxaban was significantly associated with a reduced risk of IS/SE compared to VKA (NNT: 107). No significant differences were observed between apixaban and VKAs. Dabigatran and apixaban were associated with a reduced risk of major bleeding compared to VKA (NNT: 59 and 38, respectively). No significant difference was observed between rivaroxaban and VKAs regarding major bleeding. Rivaroxaban, dabigatran, and apixaban were significantly associated with a reduced risk of ICH (NNT: 205, 115, and 108, respectively).
Limitations: Heterogeneity in definitions of major bleeding across studies.
Conclusions: The NNT calculation, when approached and interpreted properly, is a practical measure of the effectiveness of a treatment. The calculation based on HRs showed that NOACs are safe and effective alternatives to VKAs in real life. 相似文献